Analyst Ratings for Myriad Genetics (MYGN) [Neutrals]
MYGN Rating Summary
MYGN Price Target Summary
- Highest: $49.00 (Piper Jaffray)
- Lowest: $22.00 (Dougherty & Co)
- Average: $33.27
Overall Rating:
NEUTRAL
Rating Trend:
=
Avg. $ Target:
$33.27 (+25.8%)
| Date | Firm | Type | Rating (Past) |
PT (Past) |
Start $ | End $ | % Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 6/14/2013 | BofA/Merrill Lynch | Downgrade | Neutral (Buy) |
N/A (N/A) |
32.01 | 26.44 | -17.4% | Details |
| 6/14/2013 | RBC Capital | Downgrade | Sector Perform (Outperform) |
32.00 (N/A) |
32.01 | 26.44 | -17.4% | Details |
| 6/13/2013 | Leerink Swann | Downgrade | Market Perform (Outperform) |
39.00 (N/A) |
33.92 | 26.44 | -22.05% | Details |
| 5/31/2013 | Jefferies » Updated 6/14/2013 |
Downgrade | Hold (Buy) |
31.00 (N/A) |
32.17 | 26.44 | -17.81% | Details |
| 2/5/2013 | Ladenburg Thalmann | Downgrade | Neutral (Buy) |
N/A (N/A) |
26.92 | 26.44 | -1.78% | Details |
| 12/3/2012 | Goldman Sachs » Updated 4/10/2013 |
Downgrade | Neutral (Buy) |
27.00 (N/A) |
28.72 | 26.44 | -7.94% | Details |
| 9/25/2012 | Credit Suisse | New Coverage | Neutral (N/A) |
28.00 (N/A) |
27.05 | 26.44 | -2.26% | Details |
| 6/18/2012 | Dougherty & Co | Downgrade | Neutral (Buy) |
22.00 (28.00) |
23.68 | 26.44 | 11.66% | Details |
| 4/6/2011 | Macquarie | New Coverage | Neutral (N/A) |
N/A (N/A) |
20.11 | 26.44 | 31.48% | Details |
| 3/17/2011 | Oppenheimer » Updated 3/4/2013 |
New Coverage | Perform (N/A) |
29.00 (31.00) |
18.64 | 26.44 | 41.85% | Details |
| 1/28/2011 | Soleil Securities | Downgrade | Hold (N/A) |
N/A (N/A) |
20.02 | 26.44 | 32.07% | Details |
| 8/11/2010 | Global Hunter Securities | Downgrade | Neutral (N/A) |
N/A (N/A) |
15.59 | 26.44 | 69.6% | Details |
